Top Stories
-
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
Topic
-
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.
Topic
-
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
-
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
Latest News
- July 11, 2017
Ilene Anesini shares why she joined Velocity, a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC.
Topic
- July 11, 2017
Alexander Small, MD, shares why he joined Velocity, a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC.
Topic
- July 10, 2017
Velocity is a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC. Columbia riders share why they joined the cause.
Topic
- May 4, 2017
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
Topic
- April 6, 2017
Columbia University scientists study tumor revertants as possible new approach to cancer therapy.
Topic
- March 28, 2017
Based on new evidence, laparoscopic surgery should be offered to most women with early-stage endometrial cancer, says Columbia’s gynecologic cancer chief.
Topic
- March 27, 2017
A public-private research effort aims to develop more accurate ways of tracking a patient’s response to cancer therapy.
Topic
- March 7, 2017
The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
- February 27, 2017
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.
Topic
- February 14, 2017
In her JAMA editorial, Columbia oncologist Dawn Hershman says clinical trials show cooling caps reduce hair loss in some women undergoing chemotherapy.
Topic
